Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alto Neuroscience, Inc. (ANRO : NYSE)

• Company Description    Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $21.97 Daily Weekly Monthly 20 Day Moving Average: 680,868 shares Shares Outstanding: 39.24 (millions) Market Capitalization: $862.15 (millions) Beta: 1.31 52 Week High: $37.48 52 Week Low: $10.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.17% -18.32% 12 Week -23.26% -25.14% Year To Date 23.43% 11.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 650 CASTRO STREET SUITE 450 - MOUNTAIN VIEW,CA 94041 USA ph: 650-200-0412 fax: - investors@altoneuroscience.com http://www.altoneuroscience.com

• General Corporate Information    Officers Amit Etkin - Chief Executive Officer; Chairman and President Nicholas Smith - Chief Financial Officer Christopher Nixon Cox - Director Andrew Dreyfus - Director Husseini Manji - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 02157Q109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 39.24 Most Recent Split Date: (:1) Beta: 1.31 Market Capitalization: $862.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 18.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -46.46 03/31/26 - -47.22 ROA 09/30/26 - - 06/30/26 - -39.09 03/31/26 - -38.81 Current Ratio 09/30/26 - - 06/30/26 - 14.85 03/31/26 - 20.52 Quick Ratio 09/30/26 - - 06/30/26 - 14.85 03/31/26 - 20.52 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 6.25 03/31/26 - 7.62 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.07 03/31/26 - 0.07 Debt-to-Capital 09/30/26 - - 06/30/26 - 6.36 03/31/26 - 6.25

Powered by Zacks Investment Research ©